ArticleCommunications biology2023
DNA origami presenting the receptor binding domain of SARS-CoV-2 elicit robust protective immune response.
Article in Communications biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 41 citations in OpenAlex.
- Intranasal vaccines by precision printing.Nature materials · 2026Article
- Rational design of topology-defined DNA nanoframeworks for antigen delivery and cross-presentation.Journal of nanobiotechnology · 2026Article
- DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.Nature biomedical engineering · 2026Article
- DNA origami vaccines program antigen-focused germinal centers.Science (New York, N.Y.) · 2026Article
- Display of clustered antigen by follicular dendritic cells tunes B-cell receptor activation.bioRxiv : the preprint server for biology · 2025Article
- Rationally designed multimeric nanovaccines using icosahedral DNA origami for display of SARS-CoV-2 receptor binding domain.Nature communications · 2024Article
- Bottom-up synthetic immunology.Nature nanotechnology · 2024Review
- Cargo quantification of functionalized DNA origami for therapeutic application.bioRxiv : the preprint server for biology · 2024Article
- DNA origami: Interrogating the nano-landscape of immune receptor activation.Biophysical journal · 2024Review
- A Multivalent DNA Nanoparticle/Peptide Hybrid Molecular Modality for the Modulation of Protein-Protein Interactions in the Tumor Microenvironment.Advanced nanobiomed research · 2024Article
- Design and Characterization of a Gene-Encoding DNA Nanoparticle in a Cell-Free Transcription-Translation System.ACS applied nano materials · 2024Article
- Functionalizing DNA Origami by Triplex-Directed Site-Specific Photo-Cross-Linking.Journal of the American Chemical Society · 2024Article
- Purification of DNA Nanoparticles Using Photocleavable Biotin Tethers.ACS applied materials & interfaces · 2024Article
- Antigen spacing on protein nanoparticles influences antibody responses to vaccination.Cell reports · 2023Article
- Review
- Customized Scaffolds for Direct Assembly of Functionalized DNA Origami.ACS applied materials & interfaces · 2023Article
- Functional nucleic acids as potent therapeutics against SARS-CoV-2 infection.Cell reports. Physical science · 2023Review
- Dynamic RNA synthetic biology: new principles, practices and potential.RNA biology · 2023Review
- Innate Immune Stimulation Using 3D Wireframe DNA Origami.ACS nano · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Effective and safe vaccines are invaluable tools in the arsenal to fight infectious diseases. The rapid spreading of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the coronavirus disease 2019 pandemic has highlighted the need to develop methods for rapid and efficient vaccine development. DNA origami nanoparticles (DNA-NPs) presenting multiple antigens in prescribed nanoscale patterns have recently emerged as a safe, efficient, and easily scalable alternative for rational design of vaccines. Here, we are leveraging the unique properties of these DNA-NPs and demonstrate that precisely patterning ten copies of a reconstituted trimer of the receptor binding domain (RBD) of SARS-CoV-2 along with CpG adjuvants on the DNA-NPs is able to elicit a robust protective immunity against SARS-CoV-2 in a mouse model. Our results demonstrate the potential of our DNA-NP-based approach for developing safe and effective nanovaccines against infectious diseases with prolonged antibody response and effective protection in the context of a viral challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.